NCT05023980 · OUTCOME

To Evaluate the Effectiveness of Arm A Compared to Arm B: Overall Survival (OS)

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) · Source last updated 2026-09-25

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Up to approximately 5 years

What was measured

Assessments of effectiveness include OS, assessed by investigator

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2028-10
denom Units Selected: Participants
description: Assessments of effectiveness include OS, assessed by investigator
reporting Status: NOT_POSTED
time Frame: Up to approximately 5 years
title: To Evaluate the Effectiveness of Arm A Compared to Arm B: Overall Survival (OS)
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-aad7e863b8b06225cd4e94e7

Preserved source evidence · Not medical advice